These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 3839485)

  • 1. Cholinergic-muscarinic receptors participate in growth hormone secretion induced by lysine-8-vasopressin in man.
    Coiro V; Volpi R; Muzzetto P; Caiazza A; Petrolini R; Cerri L; Ruberti G; Chiodera P
    Horm Metab Res; 1985 Jun; 17(6):316-7. PubMed ID: 3839485
    [No Abstract]   [Full Text] [Related]  

  • 2. Participation of cholinergic muscarinic receptors in glucagon- and arginine-mediated growth hormone secretion in man.
    Delitala G; Frulio T; Pacifico A; Maioli M
    J Clin Endocrinol Metab; 1982 Dec; 55(6):1231-3. PubMed ID: 6897069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pirenzepine on apomorphine-induced growth hormone secretion in man.
    Massara F; Tangolo D; Demislis K; Goffi S; Bertagna A; Molinatti GM
    Panminerva Med; 1984; 26(3):167-9. PubMed ID: 6549208
    [No Abstract]   [Full Text] [Related]  

  • 4. Muscarinic receptor blockade by pirenzepine: effect on prolactin secretion in man.
    Masala A; Alagna S; Devilla L; Rovasio PP; Rassa S; Faedda R; Satta A
    J Endocrinol Invest; 1982; 5(1):53-5. PubMed ID: 6808052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholinergic-muscarinic receptors do not mediate growth hormone release in response to baclofen, a gamma-aminobutyric acid agonist, in humans.
    Coiro V; Volpi R; Dassò L; Marchesi C; Castelli A; Rossi G; Camellini L; Chiodera P
    Horm Metab Res; 1985 May; 17(5):260-1. PubMed ID: 3839204
    [No Abstract]   [Full Text] [Related]  

  • 6. Pirenzepine blunts the nocturnal growth hormone release in insulin dependent diabetes.
    Martina V; Tagliabue M; Maccario M; Bertagna A; Ghigo E; Massara F; Camanni F
    Horm Metab Res; 1987 Sep; 19(9):449-50. PubMed ID: 3692441
    [No Abstract]   [Full Text] [Related]  

  • 7. Cholinergic mediation in dermorphin-induced growth hormone secretion in man.
    degli Uberti EC; Trasforini G; Salvadori S; Margutti A; Bianconi M; Teodori V; Tomatis R; Pansini R
    Horm Res; 1986; 24(4):251-5. PubMed ID: 3781483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subclasses of muscarinic receptors and pirenzepine. Further experimental evidence.
    Hammer R
    Scand J Gastroenterol Suppl; 1982; 72():59-67. PubMed ID: 6957998
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition by somatostatin of the release of growth hormone induced by lysine-vasopressin in normal subjects.
    Chiodera P; Coiro V
    Biomed Pharmacother; 1985; 39(6):334-7. PubMed ID: 2867793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muscarinic cholinergic modulation of insulin response to an intravenous glucose tolerance test in normal man.
    Coiro V; Chiodera P; Volpi R; d'Amato L; Camellini L; Rossi G; Pignatti D; Butturini U
    J Endocrinol Invest; 1986 Feb; 9(1):27-30. PubMed ID: 3517121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vasopressin and somatotropin secretion in man].
    Giordano G; Marugo M; Minuto F; Barreca T
    Arch Maragliano Patol Clin; 1970; 26(6):333-48. PubMed ID: 5537756
    [No Abstract]   [Full Text] [Related]  

  • 12. Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase.
    Gil DW; Wolfe BB
    J Pharmacol Exp Ther; 1985 Mar; 232(3):608-16. PubMed ID: 2579230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pirenzepine--an anticholinergic agent with selective antimuscarinic properties].
    Dotevall G; Jaup BH; Stockbrügger RW
    Lakartidningen; 1982 Oct; 79(41):3671-3. PubMed ID: 6897434
    [No Abstract]   [Full Text] [Related]  

  • 14. Evidence that cholinergic receptors of muscarinic type may modulate vasopressin release induced by metoclopramide.
    Steardo L; Iovino M; Monteleone P; Bevilacqua M; Norbiato G
    J Neural Transm Gen Sect; 1990; 82(3):213-7. PubMed ID: 2248733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of cholinergic receptors blockade by atropine on growth hormone (GH)--releasing hormone (GHRH)--induced GH release in active or surgically cured acromegaly.
    Giusti M; Lomeo A; Mazzocchi GC; Attanasio R; Sessarego P; Mignone D; Fortini P; Giordano G
    Minerva Endocrinol; 1988; 13(2):87-94. PubMed ID: 3139980
    [No Abstract]   [Full Text] [Related]  

  • 16. Nicotinic-cholinergic involvement in arginine-vasopressin response to insulin-induced hypoglycemia in normal men.
    Coiro V; Butturini U; Gnudi A; Delsignore R; Volpi R; Chiodera P
    Metabolism; 1986 Jul; 35(7):577-9. PubMed ID: 3523115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirenzepine and exocrine secretions: a selective agent for gastric glands?
    Dobrilla G; Lucchin L; Comberlato M; Coruzzi G; Bertaccini G
    Hepatogastroenterology; 1983 Dec; 30(6):246-8. PubMed ID: 6144623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central administration of the muscarinic receptor subtype-selective antagonist pirenzepine selectively impairs passive avoidance learning in the mouse.
    Caulfield MP; Higgins GA; Straughan DW
    J Pharm Pharmacol; 1983 Feb; 35(2):131-2. PubMed ID: 6131987
    [No Abstract]   [Full Text] [Related]  

  • 19. Determination of the muscarinic receptor subtype mediating vasodilatation.
    Eglen RM; Whiting RL
    Br J Pharmacol; 1985 Jan; 84(1):3-5. PubMed ID: 3838488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The putative M1 muscarinic receptor does not regulate phosphoinositide hydrolysis. Studies with pirenzepine and McN-A343 in chick heart and astrocytoma cells.
    Brown JH; Goldstein D; Masters SB
    Mol Pharmacol; 1985 May; 27(5):525-31. PubMed ID: 2581122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.